TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12848392
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (60 g x day(-1))
Study: 10594483
Drug: Fantofarone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fantofarone 100 mg
Study: 10594483
Drug: Fantofarone 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fantofarone 300 mg
Study: 8546738
Drug: cM‐T412 monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: cM‐T412 monoclonal antibody, 50 mg/day for 5 days, followed by 50 mg/week for 5 weeks (6 patients) or retreatment of 50 mg/day for 5 days after 5 weeks (6 patients)
Study: 1986287
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of cyclosporine per kilogram per day
Study: 1986287
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of cyclosporine per kilogram per day
Study: 1986287
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of cyclosporine per kilogram per day
Study: 7423283
Drug: PGE2 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 4.5 mg in the form of 0.5 mg oral tablets
Study: 7423283
Drug: PGE2 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 4.5 mg in the form of tylose gel
Study: 27734072
Drug: Argatroban therapy
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban therapy initiated on the same day
Study: 27734072
Drug: Argatroban therapy
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban therapy delayed by one or more days
Study: 25577176
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) administration
Study: 24772726
Drug: Probiotic formulation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic formulation containing Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12
Study: 15220012
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg QD initially, titrated to max 45 mg)
Study: 15220012
Drug: Glimepiride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (2 mg QD initially, titrated to max 8 mg)
Study: 11527474
Drug: rhGH administered
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH administered subcutaneously daily at bedtime
Study: 11527474
Drug: Structured resistance
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured resistance exercise with placebo injections
Study: 11527474
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections only
Study: 9239456
Drug: Test patch
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test patch (MenorestTM) at 37.5 micrograms E2/day
Study: 9239456
Drug: Test patch
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test patch (MenorestTM) at 50 micrograms E2/day
Study: 9239456
Drug: Test patch
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test patch (MenorestTM) at 75 micrograms E2/day
Study: 9239456
Drug: Reference patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference patch at 50 micrograms E2/day
Study: 3102323
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (600 mg/100 ml) by enema
Study: 3102323
Drug: Prednisolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (20 mg/100 ml) by enema
Study: 4932544
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride (200 mg daily)
Study: 31957417
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine gel (CG gel)
Study: 27709225
Drug: Acarbose (20-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (20-week treatment)
Study: 27709225
Drug: Rosiglitazone (24-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (24-week treatment on top of metformin)
Study: 22094635
Drug: MenACWY-CRM coadministered
Normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM coadministered with routine vaccines
Study: 17709295
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg levetiracetam
Study: 17709295
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg topiramate
Study: 12042580
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg for infants and 20 mg for older children)
Study: 10442852
Drug: Isoprenaline (0.1-0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (0.1-0.8 microg/min) with L-NMMA (3.0 mg/kg over 5 min, followed by 30 microg/kg/min over 75 min)
Study: 10442852
Drug: Isoprenaline (0.1-0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (0.1-0.8 microg/min) with L-NMMA (6.0 mg/kg over 5 min, followed by 60 microg/kg/min over 75 min)
Study: 8674563
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g of Augmentin (co‐amoxiclav) i.v. at induction of anaesthesia
Study: 2190041
Drug: Verapamil, 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil, 320 mg/day
Study: 2190041
Drug: Ethmosine, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethmosine, 800 mg/day
Study: 2190041
Drug: Ethacizine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethacizine, 150 mg/day
Study: 32799
Drug: Lormetazepam (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam (0.5, 1, 2, 4, 8 mg)
Study: 32799
Drug: Pentobarbital (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital (100 mg)
Study: 30916575
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk (Prolacta Bioscience, Duarte, CA) administered from day -3 until day +14 after BMT
Study: 24276097
Drug: Negative-pressure wound
Normalized name: Microcyn Negative-Pressure Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure wound therapy (NPWT) applied to open fractures in the 2008-2009 cohort.
Study: 19731848
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 70% isopropyl alcohol (IPA)
Study: 17909211
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (for chronic low back pain)
Study: 9566477
Drug: No pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacological treatment (Control)
Study: 7816261
Drug: Low-dose cyclosporin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporin A (CsA) treatment at a mean dose of 3.23 mg/kg/day for 12 months
Study: 7816261
Drug: Low-dose cyclosporin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporin A (CsA) treatment
Study: 2975147
Drug: Thiopental and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental and NLA drugs
Study: 28926296
Drug: Urokinase (100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase (100,000 IU, three doses, 12-hourly)
Study: 23073171
Drug: Conjugated Linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated Linoleic Acid (CLA) supplementation (3g daily for 30 days)
Study: 23073171
Drug: Placebo (PLC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLC) supplementation (3g daily for 30 days)
Study: 21626077
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) nicardipine initiated within 3 hours of onset of ICH and continued for the next 24 hours
Study: 30217640
Drug: Vasoactive medications
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive medications
Study: 16634837
Drug: B‐vitamins (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: B‐vitamins (50 mg thiaminhydrochlorid, 50 mg pyridoxine, and 0.05 mg cyanocobalamin), plus 5 mg folic acid daily for 6 weeks
Study: 31069056
Drug: Alternative therapies
Normalized name: HERBS/ALTERNATIVE THERAPIES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative therapies
Study: 9663826
Drug: Intravenous standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous standard heparin (subcutaneous in two patients), adjusted to provide standard anticoagulant activity.
Study: 9663826
Drug: Heparin (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (second occasion during a relapse)
Study: 9663826
Drug: Heparin (general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (general treatment)
Study: 31924334
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg IV every 2 weeks until disease progression or intolerable toxicity
Study: 23250818
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (50,000 IU weekly for 12 months)
Study: 14519707
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (conjugated equine estrogen, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d)
Study: 10534147
Drug: Chinese medicinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicinal herbs (seven pills containing a standardized preparation of 35 Chinese herbs, four daily doses for 6 months)
Study: 7159001
Drug: Clindamycin-gentamycin combination
Normalized name: clindamycin, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin-gentamycin combination
Study: 25571338
Drug: Tizanidine (α2-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (α2-adrenergic agonist), administered over a 4-week program
Study: 22748458
Drug: Bundle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bundle treatment
Study: 18195164
Drug: Low-carbohydrate diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate diet (20 g of carbohydrates)
Study: 10792114
Drug: Misoprostol 100
Normalized name: MISOPROSTOL 100MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 100 microg daily
Study: 1734572
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine sulfate (EPI)
Study: 1734572
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine sulfate (IM)
Study: 1734572
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled morphine sulfate (PCA)
Study: 6734037
Drug: Nalbuphine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (30 mg)
Study: 6734037
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nalbuphine (30 mg) and acetaminophen (650 mg)
Study: 29463159
Drug: 5% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% urea lotion
Study: 27367745
Drug: Difluprednate 0.05%
Normalized name: DIFLUPREDNATE 0.05% EMULSION,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difluprednate 0.05% four times daily
Study: 24677110
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate 1% eight times daily
Study: 16050943
Drug: Pramlintide (0.1-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (0.1-1 mg daily or 0.1-0.8 mg four times a day for 5 or 6 days)
Study: 16050943
Drug: Pramlintide (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (30, 100 or 300 microg three times daily for 14 days)
Study: 16050943
Drug: Pramlintide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (various doses as mentioned)
Study: 14763223
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of cinnarizine (20 mg) and dimenhydrinate (40 mg) (Arlevert [ARL])
Study: 14763223
Drug: Betahistine dimesylate
Normalized name: betahistine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine dimesylate (12 mg)
Study: 14763223
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of cinnarizine and dimenhydrinate (ARL)
Study: 8952010
Drug: Vigabatrin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 2 g/day
Study: 7056952
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) at 1600 mg/day
Study: 7056952
Drug: Fluocortin butylester
Normalized name: fluocortin
DrugBank: Fluocortin (DB13223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortin butylester (FCB) used well in excess of its presumed therapeutic dose range
Study: 19191674
Drug: T80/H25 fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: T80/H25 fixed-dose combination (FDC)
Study: 19191674
Drug: T80/H25 fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: T80/H25 fixed-dose combination (FDC) with additional antihypertensive medication
Study: 9296409
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml 0.17% bupivacaine in 2.66% dextrose without fentanyl (Group I)
Study: 9296409
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml 0.17% bupivacaine in 2.66% dextrose with 10 microg fentanyl (Group II)
Study: 27642130
Drug: GEN-003 vaccine
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN-003 vaccine
Study: 23392542
Drug: B6 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: B6 (250 mg/day) for five months
Study: 23392542
Drug: B1+B6 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: B1+B6 (250 mg/day each) for five months
Study: 9164897
Drug: sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release verapamil
Study: 7695185
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug therapy to prevent restenosis
Study: 7695185
Drug: Local delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local delivery of drug at the site of injury
Study: 7695185
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of highly specific drugs including local gene therapy
Study: 2687007
Drug: Miglitol 50
Normalized name: miglitol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol 50 mg
Study: 2687007
Drug: Miglitol 100
Normalized name: miglitol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol 100 mg
Study: 2687007
Drug: Miglitol 75
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol 75 mg
Study: 2687007
Drug: Miglitol 200
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol 200 mg
Study: 363071
Drug: Butacote (enteric-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butacote (enteric-coated phenylbutazone) 300 mg daily
Study: 31030296
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC; 20 mg/kg)
Study: 23517509
Drug: Implant with
Normalized name: ocular implant with insertion tool for ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant with dual acid-etched surface and CaP nanoparticles
Study: 23517509
Drug: Control implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control implant with dual acid-etched surface
Study: 10870784
Drug: Continue exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue exercise (5 or more times weekly)
Study: 10870784
Drug: Reduce exercise
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduce exercise (to 3 or fewer sessions of exercise weekly)
Study: 9234649
Drug: Yohimbine 5.4
Normalized name: yohimbine 5.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 5.4 mg t.i.d.
Study: 9234649
Drug: Yohimbine 10.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 10.8 mg t.i.d.
Study: 9234649
Drug: Yohimbine 16.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 16.2 mg t.i.d.
Study: 9234649
Drug: Yohimbine 21.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 21.6 mg b.i.d.
Study: 23161001
Drug: Yohimbine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (all doses)
Study: 8129993
Drug: Cyclic mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclic mebendazole therapy
Study: 8129993
Drug: Continuous mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous mebendazole therapy
Study: 25156886
Drug: APV (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: APV (weekly vinblastine)
Study: 23364472
Drug: 17DD yellow
Normalized name: YELLOW 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17DD yellow fever vaccine (17DD‐YFV) at doses from 27,476 IU to 31 IU
Study: 12678140
Drug: Bitter melon
Normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter melon ingestion (patient treatment group)
Study: 10781759
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin 375 mg/day to 3,000 mg/day
Study: 10781759
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin 1,000 mg/day to 3,000 mg/day
Study: 8641928
Drug: G‐CSF administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF administered as required (single injections, n = 21)
Study: 8641928
Drug: G‐CSF administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF administered for at least 3 consecutive days (n = 20)
Study: 8641928
Drug: G‐CSF (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (both groups)
Study: 29767802
Drug: START-Play intervention
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: START-Play intervention (individualized twice-weekly home intervention for 12 weeks)
Study: 24549105
Drug: Risperidone or
Normalized name: risperidone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone or aripiprazole (antipsychotic treatment) for 12 weeks
Study: 11028837
Drug: Oral tropisetron
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tropisetron (5 mg once daily) for 15 days
Study: 11028837
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron (2 x 8 mg daily) for 15 days
Study: 8861177
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg twice daily
Study: 8861177
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg once daily
Study: 8861177
Drug: Venlafaxine (increased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (increased to 75 mg twice daily after 2 weeks if inadequate response)
Study: 6348585
Drug: Pergolide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (mean daily dose 3.3 mg, range 0.7 to 7.2 mg)
Study: 6348585
Drug: Bromocriptine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (mean daily dose 42.7 mg, range 5.8 to 87.5 mg)
Study: 30144034
Drug: Bilateral Greater
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral Greater Occipital Nerve Block (GONB) with 6 mL of 0.5% bupivacaine
Study: 30144034
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection with 1 mL of 0.5% bupivacaine
Study: 25317545
Drug: Butorphanol 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 0.015 mg/kg
Study: 27367987
Drug: Butorphanol 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 0.03 mg/kg
Study: 21480777
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded implants (40 patients, minimal insertion torque 30 Ncm) with nonoccluding temporary restorations.
Study: 21480777
Drug: Early loaded
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loaded implants (40 patients) with definitive restoration after 2 months.
Study: 12150267
Drug: Traditional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapies appropriate for the patient
Study: 12150267
Drug: Therapies appropriate
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies appropriate for the patient with an oral vertical exercise device
Study: 12150267
Drug: Home care
Normalized name: Alpha Dent Home Care 0.4% Fluoride Treatment Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home care education and use of the oral exercise device
Study: 9797793
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lovastatin after 120 mg diltiazem twice a day for 2 weeks
Study: 9797793
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pravastatin after 120 mg diltiazem twice a day for 2 weeks
Study: 8109598
Drug: r-HuEPO administration
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-HuEPO administration
Study: 28882919
Drug: THC:CBD oromucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC:CBD oromucosal spray (Sativex)
Study: 23578552
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA), daily administration, dosage not specified, duration of therapy not specified.
Study: 18165591
Drug: IP meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP meperidine 50 mg
Study: 18165591
Drug: IP meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP meperidine 100 mg